SeeThruEquity Issues Update on Propanc Health Group Corp (OTCQB: PPCH)

NEW YORK, NY / ACCESSWIRE / February 28, 2017 / SeeThruEquity, a leading independent equity research and corporate access firm focused on small-cap and micro-cap public companies, today announced it has issued an update on Propanc Health Group Corp (OTCQB: PPCH).

The report is available here: PPCH February 2017 Update Note.

Propanc is an Australian-based biotechnology company seeking to develop new long term treatments for cancer. The company’s research and development activities have been focused on anti-cancer compounds targeting cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers. Propanc’s formulation of anti-cancer compounds utilizes pro-enzyme therapy. Its lead drug candidate, PRP, is a patented formulation consisting of two proenzymes, trypsinogen (T) & chymotrypsinogen (C) from bovine pancreas. PRP targets malignant cancer cells through multiple pathways, which the company believes may create a lasting clinical benefit for the patient. Propanc is currently completing non-clinical studies and intends to undertake Phase I, II and III clinical trials to assess the safety and efficacy of their product in specific patient populations. The company has also stated that it is pursuing strategic partners in the industry, and that it hopes to have meaningful discussions with potential partners following the release of new data.

Additional highlights from the update note are as follows:

Propanc CEO provides positive investor update

Propanc CEO, James Nathanielsz provided a detailed investor update in January, highlighting accomplishments by the company in 2016 and outlining its clinical plans as the company seeks to begin a Phase 1 human study by the end of 2017. Key accomplishments during 2016 included a successful scientific advice meeting with the Medicines and Healthcare Products Regulatory Agency, MHRA, in the UK, during which the company defined the non-clinical and clinical development pathway for PRP. Other accomplishments included developing an enzyme linked immunosorbent assay (ELISA) method, executing a manufacturing agreement with Belgium-based AmatsiQBiologicals, and developing a new infrared dye-labelled detection method for trypsinogen and chymotrypsinogen, the proenzymes used in PRP.

Propanc receives US patent allowance

Importantly Propanc has made progress advancing its intellectual property protection. The company submitted four new patents in the US, Australia and Spain, during 2016, relating to dosage and mechanism of action for its two proenzymes used in PRP, two proenzymes, trypsinogen (T) & chymotrypsinogen (C). Importantly, in January, Propanc received a notification of allowance from the US Patent Office providing coverage for a method of treating a solid tumor through administering a pharmaceutical composition comprising a therapeutically effective amount of trypsinogen and chymotrypsinogen to patients, a noteworthy accomplishment.

Low dose group 28-day GLP-compliant toxicity study complete

Looking ahead to 2017, Propanc is quickly moving to initiate a Phase 1 clinical trial for PRP by the end of the year. The company took a step in that direction recently, with the announcement that it had successfully completed the low dose group for its GLP-compliant 28-day repeat dose toxicity study. With no safety concerns in the low dose group, Propanc received approval to proceed with the middle and high dose groups from the International Animal Care & Use Committee (IACUC) in Melbourne, Australia.

Updating price target to $0.05 for PPHC

We are updating our price target to $0.05 for PPCH. This reflects the increase in shares since our initial valuation of the company in 2015 and continued capital needs, offset by the large opportunity targeted by the company with new potential therapies for pancreatic, ovarian and colorectal cancer. We continue to see Propanc as an intriguing microcap biotechnology company with a pre-clinical therapeutic pipeline targeting end markets with multi-billion dollar potential if the company can show efficacy in clinical trials and execute on a partner-based strategy for regulatory approval and commercialization.

Please review important disclosures on our website at www.seethruequity.com.

About Propanc Health Group Corporation

Propanc is developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes. In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. www.Propanc.com.

About SeeThruEquity

Since its founding in 2011, SeeThruEquity has been committed to its core mission: providing impactful, high quality research on underfollowed smallcap and microcap equities. SeeThruEquity has pioneered an innovative business model for equity research that is not paid for and is unbiased. SeeThruEquity is the host of acclaimed investor conferences that are the ultimate event for publicly traded companies with market capitalizations less than $1 billion.

SeeThruEquity is approved to contribute its research reports and estimates to Thomson One Analytics (First Call), the leading estimates platform on Wall Street, as well as Capital IQ and FactSet. SeeThruEquity maintains one of the industry’s most extensive databases of opt-in institutional and high net worth investors. The firm is headquartered in Midtown Manhattan in New York City.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 456158